Key Takeaways BMRN will acquire all FOLD shares for $14.50 in cash, valuing the deal at $4.8B.The deal adds Galafold and Pombiliti-Opfolda, which added $449M in sales in the first nine months of 2025.BMRN will also gain U.S. rights to a late-stage drug DMX-200 being developed for a rare kidney disease.BioMarin Pharmaceutical (BMRN) announced that it entered a definitive agreement to acquire all outstanding shares of Amicus Therapeutics (FOLD) for $14.50 per share in cash, totaling $4.8 billion.The deal, app ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top Upgrades: More bullish on the name, Bradesco BBI upgraded Volaris (VLRS) to Outperform from Neutral with a $12 price target.Loop Capital upgraded Ollie's Bargain Outlet (OLLI) to Buy from Hold with a price target of $135, up from $130, following a recent store tour. The firm believes investors are underestimating Ollie's comp ...

We recently published 10 Firms in the Limelight. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best performers on Friday. Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece as investors gobbled up shares following announcements that it would merge with Biomarin Pharmaceutical for nearly $5 billion. At intra-day trading, the stock climbed to its highest price of $14.36 before trimming gains to finish the day just up by 30.21 percent at $14.1 ...

公司评级与股价动态 - Needham将Amicus Therapeutics的股票评级从买入下调至持有 股票价格为14.21美元[1] - 尽管评级下调 FOLD股价仍出现显著上涨 当前股价为14.20美元 涨幅达30.43% 上涨3.31美元[3] - 股价在14.16美元至14.36美元之间波动 创下过去一年最高价[3] 收购交易详情 - BioMarin Pharmaceutical收购Amicus Therapeutics 交易价值为48亿美元[2] - 该交易为全现金交易 旨在通过获得Amicus的两种罕见病药物来增强BioMarin的产品组合[2][5] - 此次收购预计将加强BioMarin的市场地位并推动未来增长[5] 公司市场表现与数据 - FOLD的市值约为43.8亿美元 交易量约为1.328亿股[4] - 该股过去一年的最低价格为5.51美元 表明其经历了显著增长[4] - 随着交易推进 BioMarin的收购预计将进一步影响FOLD的市场表现[4] 行业趋势与影响 - 此次收购反映了生物技术行业整合的广泛趋势 公司旨在扩大其能力和产品供应[2] - 这笔48亿美元的交易突显了行业正在进行的整合趋势[5]

投资者商业日报网站信息 - 网站提供多种股票市场分析工具与服务 包括IBD股票图表 IBD股票检查 股票报价 今日股市 大市概况 我的股票列表等 [3][4] - 网站提供高级投资研究平台与服务 包括IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem等 [4] - 网站内容关联道琼斯旗下其他财经媒体 包括华尔街日报 巴伦周刊 MarketWatch 道琼斯聪明钱等 [4] - 网站信息来源于其认为可靠的渠道 但不对其准确性 及时性或适用性提供保证 [2] - 网站信息可能随时变更 不构成对买卖任何证券的要约 推荐 招揽或评级 [2] - 历史投资表现不能作为未来成功的指示或保证 文章作者/主讲人可能持有其讨论的股票 [2][5] - 网站不对投资任何特定证券或使用特定投资策略的可取性做出任何陈述或保证 [5] - 实时报价由纳斯达克最后销售价提供 并非来自所有市场 所有权数据由伦敦证券交易所集团提供 预估数据由FactSet提供 [5] 公司商标与版权 - IBD IBD Digital IBD Live IBD Weekly Investor's Business Daily Leaderboard MarketDiem MarketSurge及其他标志均为投资者商业日报有限责任公司拥有的商标 [6] - 网站内容版权归2025年投资者商业日报有限责任公司所有 保留所有权利 [6]

美股市场表现 - 美股盘中走高 纳斯达克综合指数上涨超过1% [1] - 道琼斯指数上涨0.55%至48,216.43点 纳斯达克指数上涨1.10%至23,260.50点 标普500指数上涨0.83%至6,830.85点 [1] - 信息技术板块领涨 涨幅达1.6% 必需消费品板块下跌0.4% [1] 个股重大异动 - 耐克公司股价下跌约10% 尽管其二季度营收124.3亿美元及每股收益0.53美元均超预期 但毛利率连续第二个季度下滑 [2] - Autozi Internet Technology股价飙升54%至2.34美元 公司宣布其战略投资者确认了9000万美元的初始股权投资 [9] - Amicus Therapeutics股价大涨31%至14.20美元 BioMarin Pharmaceutical同意以约48亿美元的总股权价值收购该公司 BioMarin股价亦上涨19%至61.88美元 [9] - Lamb Weston Holdings股价下跌25%至44.70美元 此前公司公布第二季度业绩 [9] - BlackBerry股价下跌10%至3.90美元 此前公司公布第三季度业绩 [9] - Mangoceuticals股价下跌45%至0.72美元 公司宣布了一项规模高达1亿美元、专注于Solana的数字资产国库策略 [9] 商品市场动态 - 原油价格上涨0.9%至56.66美元 黄金价格上涨0.4%至4,381.60美元 [5] - 白银价格大涨3.4%至67.415美元 铜价上涨1.1%至5.4955美元 [5] 全球其他市场 - 欧洲股市普遍上涨 欧元区STOXX 600指数上涨0.37% 英国富时100指数上涨0.61% 德国DAX 40指数上涨0.37% 法国CAC 40指数微涨0.01% [6] - 亚太市场周五收高 日本日经225指数上涨1.03% 香港恒生指数上涨0.75% 中国上证综指上涨0.36% 印度BSE Sensex指数上涨0.53% [7] 宏观经济数据 - 美国11月成屋销售环比增长0.5% 折合年率为413万套 [10]

U.S. stocks were higher, with the Dow Jones index gaining more than 250 points on Friday.Shares of Carnival PLC (NYSE:CUK) rose sharply during Thursday's session after the company announced better-than-expected fourth-quarter adjusted EPS results and issuedFY26 adjusted EPS guidance above estimates.Carnival shares jumped 16.3% to $30.61 on Friday.Here are some other big stocks recording gains in today’s session.NovaBay Pharmaceuticals Inc (NYSE:NBY) shares jumped 45.1% to $4.28.Intuitive Machines Inc (NASDA ...

收购交易概述 - 渤健制药宣布将以约48亿美元的价格收购阿米库斯治疗公司 [1][3] - 收购旨在扩大公司在罕见代谢性疾病领域的业务版图 [1][3] 交易条款与市场反应 - 渤健将以每股14.50美元的价格收购阿米库斯治疗公司股份，较该公司最新收盘价溢价33.1% [1][3] - 消息宣布后，阿米库斯治疗公司股价暴涨30%，渤健股价在盘前交易中也上涨了近5% [1][3] 收购标的资产与产品组合 - 通过交易，渤健将获得阿米库斯治疗公司已获批的多款遗传病治疗药物 [1][3] - 获得产品包括治疗法布里病的口服药加拉福 [1][3] - 获得产品还包括用于治疗庞贝病的复方疗法庞比利提联合奥福达 [1][3] - 阿米库斯治疗公司还拥有治疗局灶节段性肾小球硬化症的在研药物DMX-200的美国市场授权 [1][3] 交易资金来源 - 渤健计划通过现有现金储备与约37亿美元的非可转债融资相结合的方式为收购提供资金 [1][3] - 截至9月30日，渤健的现金及投资总额约为20亿美元 [2][4] 交易时间线与财务影响 - 此项收购预计将于2026年第二季度完成交割 [2][4] - 交易完成后将立即为公司带来营收增长 [2][4] - 交易完成后的首个12个月内，此次收购预计将提升公司调整后利润 [2][5] - 自2027年起，该笔交易将为公司带来显著的收益增厚 [2][5]

MILWAUKEE, Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you. In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at a ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amicu. ...